InSCREENeX GmbH

Their core work

InSCREENeX GmbH is a German biotech SME that develops in vitro cellular screening systems — tools that recreate human disease conditions in a lab dish, enabling drug developers to test compounds on patient-derived cells rather than relying solely on animal models. Their O-POINTED project had them coordinating the development of personalised cellular drug development tools for osteoarthritis, working with patient cohort-derived cells to build disease-relevant assay platforms. They also contribute technical expertise to veterinary and infectious disease research, as shown by their participation in VetBioNet, a European network of high-containment BSL3 animal infectiology facilities. In practice, they sit at the intersection of cell biology, drug screening, and disease modelling — a rare combination for a company of their size.

What they specialise in

How they've shifted over time

In their first H2020 project (2017), InSCREENeX joined a large infrastructure network centred on veterinary BSL3 facilities and infectious disease preparedness — a supporting role that likely reflected demand for their cell-based tools within pathogen research contexts. By 2019, they led their own SME Instrument Phase 1 project targeting osteoarthritis, shifting focus toward personalised medicine and patient-derived cellular models for human disease. The trajectory suggests a company that started as a niche technology supplier to biosafety infrastructure and then moved toward commercialising proprietary cell screening platforms in the drug development market.

InSCREENeX appears to be moving from supporting roles in large research infrastructure networks toward leading their own drug development tool commercialisation — a path typical of deeptech SMEs transitioning from research services to product-led growth.

How they like to work

InSCREENeX has operated both as a coordinator (O-POINTED) and as a participant (VetBioNet), showing they can take on both leadership and supporting roles depending on project scope. The VetBioNet participation connected them to a broad consortium of 27 partners across 12 countries, though this network reflects that project's infrastructure character rather than a dense web of long-term collaborators. With only two projects in the dataset, it is too early to identify repeating partners or stable consortium preferences.

InSCREENeX has collaborated with 27 unique partners across 12 countries, primarily through the large VetBioNet infrastructure consortium. Their geographic reach is European, with no identifiable single-country cluster from the available data.

What sets them apart

InSCREENeX is a rare type of SME that bridges two normally separate worlds: high-containment infectious disease research (BSL3/veterinary) and personalised in vitro drug development tools. Their name — referencing in vitro screening — signals a proprietary cell platform that they have applied in both animal health and human musculoskeletal disease contexts. For a consortium builder, they offer a small, agile partner with specialised cell biology capabilities that are difficult to source from academic labs or large contract research organisations.

Highlights from their portfolio

• VetBioNet
  A long-running RIA infrastructure project (2017-2023) connecting European BSL3 veterinary facilities — notable for its scale and for providing InSCREENeX with the bulk of their EC funding (€111,294) and their entire documented partner network.
• O-POINTED
  InSCREENeX's only coordinator role — an SME Instrument Phase 1 project applying patient-derived cellular models to osteoarthritis drug development, signalling their ambition to commercialise proprietary screening technology beyond infectious disease research.